Purpose Pancreatic cancer is the fourth leading cancer-related mortality disease in the
United States, with a five-year survival rate of 11%, and only 10 15% of all pancreatic
cancer patients are operable or borderline operable.
Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however,
biomarkers related to this are not well understood. This study aims to identify
biomarkers for the early diagnosis of pancreatic cancer through duodenal pancreatic
juice, which can be easily obtained through an endoscopy.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT07030348.
Locations matching your search criteria
United States
Colorado
Aurora
UCHealth University of Colorado HospitalStatus: Active
Name Not Available
Pancreatic cancer is the fourth leading cancer-related mortality disease in the United
States, with a five-year survival rate of 11%, which is a very poor prognosis, and only
10-15% of all pancreatic cancer patients are operable or borderline operable.
Therefore, there is an unmet need for early diagnosis of pancreatic cancer; however, the
biomarkers of humoral fluids associated with the early diagnosis of pancreatic cancer are
not well understood.
Duodenal pancreatic fluids can be easily obtained through an endoscopy and contain a
large amount of pancreatic fluid secreted by the pancreas, which is known to be a
candidate of biomarkers for early diagnosis of pancreatic cancer.
However, there have been few studies using duodenal fluids in Korea. This study aims to
prospectively analyze biomarkers for early diagnosis of pancreatic cancer using duodenal
fluids obtained by endoscopy in pancreatic and non-pancreatic cancer groups.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationDo Hyun Park
